Inflammatory Bowel Disease

CHARLOTTE, N.C. — Withholding immunosuppressive therapy prior to or following COVID-19 vaccination did not impact the rate of breakthrough infection or hospitalizations in patients with inflammatory bowel disease, noted a presenter here.

Older patients with inflammatory bowel disease receiving vedolizumab, particularly those with Crohn’s disease, faced higher risk of treatment failure compared with patients receiving tumor necrosis factor antagonists.

Histologically and clinically active inflammatory bowel disease increased the risk for preterm birth, especially for women with ulcerative colitis, researchers reported.

CHARLOTTE, N.C. — Bringing together the leaders in gastroenterology during the American College of Gastroenterology Annual Meeting, Healio recognized eight Disruptive Innovators.

Inflammatory bowel disease was found to have a positive association with both psoriasis and psoriatic arthritis, suggesting it is a causal risk factor for these two chronic diseases, according to a study.

Two adalimumab biosimilars, adalimumab-adaz and adalimumab-fkjp, demonstrated safety and effectiveness in patients with Crohn’s disease and ulcerative colitis, according to a study in PLOS One.

Immunosuppressed patients with inflammatory bowel disease who received a third COVID-19 vaccine demonstrated improved antibody binding, although the response was reduced in patients receiving infliximab and tofacitinib.

Men who have sex with men were more than twice as likely to develop inflammatory bowel disease compared with men who have sex with women when engaging in “high-risk” sexual activity, according to research published in Gut.

In patients with spondyloarthritis, genetics and disease activity levels likely impact the composition of gut microbiota, according to data published in Arthritis & Rheumatology.

This month’s cover story is an important reminder of just how essential cross-specialty coordination is to patient care.